Donesumab, a monoclonal antibody against RANK ligand is used for the treatment of (AIIMS Nov 2010)
|D||Systemic lupus erythematosis|
a. Receptor for activated nuclear factor KB (RANK) is present on osteoclast progenitors. Binding of RANK-ligand to these receptors causes differentiation and activation of osteoclast progenitors to mature osteoclasts.
b. Denosumab is a monoclonal antibody that prevents the binding of RANK-ligand with RANK. This prevents activation of osteoclasts and it can therefore, be used in osteoporosis.
c. Osteoblasts synthesize and release osteoprotegerin (OPG),' identical with RANK, which functions as a 'decoy receptor'. OPG thus, inhibits the binding to RANK-L to RANK. Hence OPG analogs can be the potential therapeutic agents of osteoporosis.